Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Village Farms International, Inc. and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Village Farms announced it did not receive a conditional medical license from the Texas Department of Public Safety, which was part of the Phase I license awards [3]. - Following this announcement, Village Farms' stock price decreased by $0.37 per share, representing a 9.3% decline, closing at $3.61 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Village Farms to discuss claims related to potential securities fraud [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Live Oak Bancshares, Inc. and its officers or directors, following the company's announcement of material misclassifications in its financial statements [1][3]. Group 1: Company Financials - On November 12, 2025, Live Oak disclosed that it would amend its 2024 Annual Report and Quarterly Reports for the periods ended March 31, 2025, and June 30, 2025, to restate its Consolidated Financial Statements due to errors in cash flow classifications [3]. - The company identified a material misclassification related to cash flows from the sale of loan participations, which led to a conclusion that a material weakness exists in its internal control over financial reporting [3]. - Following this announcement, Live Oak's stock price decreased by $0.80 per share, or 2.49%, closing at $31.29 per share on November 13, 2025 [3]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Live Oak Bancshares, indicating a potential class action lawsuit due to the alleged securities fraud [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation and potential participation in the class action [1][2]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a legacy of recovering significant damages for class members over its 85-year history [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Graphic Packaging Holding Company and its executives [1] Group 1: Company Performance - On December 8, 2025, Graphic Packaging announced a restructuring of its support functions and production optimization initiatives, leading to a lowered full-year core earnings and profit outlook due to ongoing production curtailments [3] - The company now expects Adjusted EBITDA to be in the range of $1.38 billion to $1.43 billion, a decrease from the previous guidance of $1.40 billion to $1.45 billion [3] Group 2: Market Reaction - Following the announcement of the lowered earnings outlook, Graphic Packaging's stock price fell by $1.35 per share, or 8.66%, closing at $14.23 per share on December 9, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Fermi Inc. and its officers or directors, following significant stock price decline after a key tenant terminated an agreement [1][3][4]. Group 1: Company Overview - Fermi Inc. completed its initial public offering (IPO) on October 1, 2025, offering 32.5 million shares at a price of $21.00 per share [3]. - The company is involved in the development of a data center campus known as Project Matador [3]. Group 2: Recent Developments - On December 12, 2025, Fermi announced that the first potential tenant for Project Matador had terminated its Advance in Aid of Construction Agreement, which involved Fermi agreeing to advance up to $150 million for construction costs [3]. - Following the announcement of the tenant's termination, Fermi's stock price dropped by $6.66 per share, representing a 43.67% decline, closing at $8.59 per share on December 15, 2025 [4]. Group 3: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of Fermi investors regarding possible securities fraud or other unlawful practices by the company and its executives [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by ADC Therapeutics and its officers or directors, following a significant stock price drop after the release of clinical trial data [1][4]. Group 1: Investigation Details - Pomerantz LLP is representing investors of ADC Therapeutics and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices [1]. Group 2: Clinical Trial Data - On December 3, 2025, ADC Therapeutics announced updated data from the LOTIS-7 Phase 1b clinical trial for ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma [3]. - The press release highlighted positive aspects of the data but also noted adverse events in two patients, with one being treatment-related, and reported that cytokine release syndrome occurred in 36.7% of patients across dose levels [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial data, ADC Therapeutics' stock price fell by $0.65 per share, representing a 14.13% decrease, closing at $3.95 per share on December 3, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving SNDL Inc. and its officers or directors [1] Group 1: Company Developments - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM Inc., maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [3] - Following the announcement of the amended agreement, SNDL's stock price decreased by $0.29 per share, or 13.12%, closing at $1.92 per share on the same day [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Air Products and Chemicals, Inc. and its officers or directors [1] Group 1: Company Developments - On December 8, 2025, Air Products announced advanced negotiations with Yara International to combine its industrial gas capabilities and low-emission hydrogen production with Yara's ammonia production, shipping, and terminals, focusing on European demand [3] - Following the announcement, Air Products' stock price decreased by $24.64 per share, or 9.45%, closing at $236.05 per share on the same day [3] Group 2: Legal Investigation - Pomerantz LLP is representing investors of Air Products in an investigation regarding possible securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ardent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On November 12, ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Lakeland Industries and its officers or directors [1] Group 1: Financial Performance - On December 8, 2025, Lakeland reported its third quarter financial results and announced the withdrawal of formal guidance, indicating a shift to a more disciplined operating model focused on measurable execution, cash generation, and transparency [3] - Following this announcement, Lakeland's stock price dropped by $5.85 per share, representing a decline of 38.97%, closing at $9.16 per share on December 10, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is conducting an investigation on behalf of investors of Lakeland Industries regarding possible securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rezolute, Inc. and its officers or directors following disappointing clinical trial results that led to a significant drop in the company's stock price [1][3]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company on NASDAQ under the ticker RZLT [1]. - The company recently announced topline results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [3]. Group 2: Clinical Trial Results - The Phase 3 study did not meet its primary endpoint, which was to assess the change in average weekly hypoglycemia events, showing only a 45% reduction in events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group [3]. - The study also failed to meet its key secondary endpoint, with a 25% reduction in average daily percent time in hypoglycemia at the 10 mg/kg dose, again not statistically significant compared to a 5% increase in the placebo group [3]. Group 3: Stock Market Reaction - Following the announcement of the clinical trial results, Rezolute's stock price fell by $9.44 per share, or 87.2%, closing at $1.77 per share on December 19, 2025 [3].